K
Ken Fujioka
Researcher at Scripps Health
Publications - 107
Citations - 9343
Ken Fujioka is an academic researcher from Scripps Health. The author has contributed to research in topics: Weight loss & Overweight. The author has an hindex of 39, co-authored 105 publications receiving 8027 citations. Previous affiliations of Ken Fujioka include Torrey Pines Institute for Molecular Studies.
Papers
More filters
Journal ArticleDOI
Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.
Steven B. Heymsfield,Andrew S. Greenberg,Ken Fujioka,Russell M. Dixon,Robert F. Kushner,Thomas K. Hunt,John A. Lubina,Janet Patane,Barbara Self,P Hunt,Mark A. Mccamish +10 more
TL;DR: Administration of exogenous leptin appears to induce weight loss in some obese subjects with elevated endogenous serum leptin concentrations and a dose-response relationship with weight and fat loss was observed with subcutaneous recombinant leptin injections in both lean and obese subjects.
Journal ArticleDOI
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer,Arne Astrup,Ken Fujioka,Frank L. Greenway,Alfredo Halpern,Michel Krempf,David C.W. Lau,Carel W. le Roux,Rafael Violante Ortiz,Christine B. Jensen,John P.H. Wilding +10 more
TL;DR: 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control in patients with type 2 diabetes and prediabetes.
Journal ArticleDOI
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway,Ken Fujioka,Raymond A Plodkowski,Sunder Mudaliar,Maria Guttadauria,J. Erickson,Dennis Dong Hwan Kim,Eduardo Dunayevich +7 more
TL;DR: Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight and was not associated with increased depression or suicidality events compared with placebo.
Journal ArticleDOI
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Carel W. le Roux,Carel W. le Roux,Arne Astrup,Ken Fujioka,Frank Greenway,David C.W. Lau,Luc Van Gaal,Rafael Violante Ortiz,John P H Wilding,Trine Vang Skjøth,Linda Shapiro Manning,Xavier Pi-Sunyer,Andreas Hamann,Alain Barakat,Matthias Blüher,Thomas Linn,Andrea Mölle,Alexander Segner,Petra Stübler,Regina Tosch-Sisting,Furio Pacini,Ferruccio Santini,Giulio Marchesini,Carlo Maria Rotella,Cecilia Invitti,Roberto Vettor,Silvio Buscemi,Pedro Mezquita Raya,Felipe Casanueva Freijoo,Ramón Gomis de Barbará,Raffaele Carraro,Enrique Romero Bobillo,Carmen de la Cuesta,Csaba Farsang,Albert Császár,Barbara Zahorska-Markiewicz,Danuta Pupek-Musialik,Edward Franek,Lucyna Ostrowska,Magdalena Olszanecka-Glinianowicz,N. Lalic,Dragan Micic,Bernhard Ludvik,Bernhard Paulweber,Rudolf Prager,André Scheen,Astrup Av,Kjeld Hermansen,Sten Madsbad,Aila Rissanen,Sakari Nieminen,Markku J. Savolainen,Michel Krempf,Monique Romon,Martine Laville,Michel Marre,Reginald Mira,Francis M. Finucane,Aletha Veenendaal,Frank van Berkum,Solrun Johannsson-Vidarsdóttir,Vivienne Van de Walle,Eelco Meesters,Jøran Hjelmesæth,Tor Ole Klemsdal,Bård Kulseng,Birgit Bach-Kliegel,Kurt Laederach,Lukas Villiger,Alain Golay,Stefan Bilz,Thozhukat Sathyapalan,Stephen C. Bain,Sudesh Kumar,Carel Wynard Le Roux,Michael E. J. Lean,Barbara McGowan,Tariq Rehman,John P.H. Wilding,Gary A. Wittert,Ian D. Caterson,Joeseph Proietto,John Prins,Bruno Geloneze Neto,Jorge Luiz Gross,Antonio Roberto Chacra,Alfredo Halpern,Henrique de Almeida Suplicy,Francis Chun Chung Chow,Hemant P Thacker,Manoj Chadha,Hemaraj Chandalia,Ambika Gopalakrishnan Unnikrishnan,Sanjay Kalra,Neeta Deshpande,Minakshi Shunmugavelu,Vaishali Deshmukh,Maximo Maislos,Gabriella Segal Lieberman,Ilan Shimon,Naftali Stern,Dan Nabriski,Eddy Karnieli,Naim Shehadeh,Guillermo Gonzalez-Galvez,Maria del Rosario Arechavaleta-Granell,Rafael Violante Ortiz,Guadalupe Morales Franco,Irina Gurieva,Lyudmila Aleksandrovna Suplotova,Ekaterina A. Troshina,Ludmila Aleksandrovna Ruyatkina,Emma Anatolievna Voychik,Sergey Martsevich,Maria A Startseva,Mary Elizabeth Seeber,Aysha Badat,Graham Ellis,Yuksel Altuntas,Serdar Güler,Ender Ulgen,Tuncay Delibasi,Tony Chetty,Randy Hart,Jeannette Janzen,Isabelle Labonte,David C.W. Lau,Joanne Liutkus,Dennis O'Keefe,Raj Padwal,Thomas Ransom,Richard Tytus,Stanley John Weisnagel,Jay Adler,Keith Aqua,S. Aronoff,Gary W. Bedel,Thomas Craig Blevins,Joe Blumenau,Andrew Peter Brockmyre,Robert S Call,Rafael Canadas,Louis B Chaykin,Kenneth Cohen,Jeffrey Keith Conrow,Matthew G Davis,H Jackson Downey,Steven Richard Drosman,Steven Duckor,H. Frank Farmer,James Farrell,Stephen Fehnel,Matthew Patrick Finneran,Ray Forbes,Alan Forker,Mark Fredrick,Steven Andrew Geller,Santosh Gill,Linda Glaser,Susan Neims Greco,Frank L. Greenway,Wayne Harper,Lee Herman,John Hoekstra,Richard Ingebretsen,Rodney Ison,Rajeev K Jain,Roy Kaplan,Steven Richard Kaster,Gregory A Haase,Boris Kerzner,Judith Lee Kirstein,William Koltun,Diane R Krieger,Cora E. Lewis,Robert Madder,Richard N Marple,Edward J McDermott,Curtis John Mello,Alan B. Miller,Julie Mullen,John Nardandrea,Patrick M. O'Neil,F. Xavier Pi-Sunyer,Ronald M Pucillo,Chanhaeng Rhee,Scott Redrick,Aaron Pardini,Jeffrey Rothman,Domenica Rubino,Gladstone Sellers,Timothy Smith,William David Byars,Joseph Soufer,Allen Michael Sussman,Kyle Patrick,Erich Lloyd Schramm,Martin Van Cleeff,Saul Reuel Berg,Holly R. Wyatt,James Alan Simon +200 more
TL;DR: Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes in this trial, with the limitation that withdrawn individuals were not followed up after discontinuation.
Journal ArticleDOI
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Priscilla Hollander,Alok Gupta,Raymond A Plodkowski,Frank L. Greenway,Harold Bays,Colleen Burns,Preston Klassen,Ken Fujioka +7 more
TL;DR: NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.